<DOC>
	<DOCNO>NCT00696410</DOCNO>
	<brief_summary>Heart failure affect 5.3 million Americans , cardiovascular disease enjoy reduction mortality rate last decade , mortality heart failure continue rise [ 1 ] . Thus , identify novel therapy reduce heart failure development and/or progression warrant . Unifying cardiomyopathic process impair handle reactive oxygen specie ( ROS ) [ 2-4 ] . Reactive oxygen specie generate byproduct inflammation oxidative stress occur set normal myocardial aerobic metabolism . Metallothionein , glutathione reductase , superoxide dismutase major antioxidant myocardium help combat oxidative stress prevent myocardial damage . In certain clinical setting , include cardiac ischemia , diabetes , heavy metal excess ( copper , iron ) , myocardial oxidative stress level greatly increase . When pro-oxidant level exceed myocardial antioxidant capability , ROS-induced membrane , protein , DNA inactivation lead development cardiac dysfunction . One mean prevent development progression cardiomyopathy reduce oxidative stress up-regulation intramyocardial antioxidant . Murine study cardiomyopathy show oral administration zinc acetate may succeed indirect myocardial anti-oxidant zinc sufficiently up-regulates intramyocardial production superoxide dismutase ( zinc-dependant anti-oxidant enzyme ) metallothionein ( `` super antioxidant '' ) [ 5-8 ] . Zinc also directly reduce prooxidant Cu level reduce gastrointestinal zinc absorption . However , date , study examine impact zinc acetate supplementation subject cardiomyopathy systolic failure antioxidant capacity remodel . The hypothesis pilot study administration oral zinc acetate human cardiomyopathy lead up-regulation myocardial anti-oxidant capability , lead favorable reduction oxidative stress . This study provide preliminary data support randomize , placebo-controlled trial zinc therapy heart failure mean improve prevent progression systolic dysfunction subject mild-moderate heart failure .</brief_summary>
	<brief_title>The Impact Zinc Supplementation Left Ventricular Function Nonischemic Cardiomyopathy</brief_title>
	<detailed_description>Altered regulation transition-metal copper ( Cu ) may lead overproduction reactive oxygen specie ( ROS ) subsequent development nonischemic cardiomyopathy ( NISCM ) . Myocardial Cu level elevate NISCM , Cu level high `` diabetic cardiomyopathy . '' In human , zinc ( Zn ) essential component proteins critical regulate myocardial cytoskeleton turnover cellular proliferation . Zn also serve antioxidant indirect regulator redox-active Cu . By upregulating chelator metallothionein , Zn reduce level free Cu implicate oxidative myocardial damage . Transgenic over-expression antioxidant metallothionein show reduce ROS-induced myocardial damage . In diabetic cardiomyopathy , Cu chelation improve leave ventricular ( LV ) diastolic relaxation abnormality . However , unknown Zn supplementation could alter progression LV systolic dysfunction Cu depletion ROS reduction . The aim pilot study assess impact novel intervention , Zn supplementation , myocardial remodel examine change serum level type I ( PINP ) III ( PIIINP ) collagen N-terminal propeptides . The primary study hypothesis Zn supplementation favorable impact pathophysiology NISCM either replete Zn deficiency/insufficiency reduce myocardial damage adverse remodel set redox-active Cu excess . Stable outpatient ( n=40 ) chronic NISCM ( ejection fraction ≤40 % ) receive daily oral Zn-acetate ( 50 mg po tid ) 10 month . Serum PINP , PIIINP , marker inflammation ( CRP , sedimentation rate , myeloperoxidase ) oxidative stress ( 8-isoprostane , superoxide dismutase ) obtain baseline follow 10 month Zn supplementation . Changes collagen turnover correlate change note LV systolic diastolic function echocardiography . Finally , examine differential treatment effect Zn therapy diabetic subset ( n=20 ) NISCM compare nondiabetics .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Zinc</mesh_term>
	<criteria>Subjects ( n=40 ) ≥21 year age chronic ( ≥1 year duration ) nonischemic cardiomyopathy ( NISCM ) , New York Heart Association ( NYHA ) functional class IIIII symptom stable medical therapy ( ≥3 month stable dos βblocker , angiotensin inhibitor receptor blocker , aldosterone inhibitor [ appropriate ] therapy ) document left ventricular ( LV ) ejection fraction ≤40 % evidence LV dilation eligible study participation . The diagnosis nonischemic etiology cardiomyopathy must support coronary angiography , stress echocardiography , nuclear scintigraphy . To allow comparison treatment effect diabetic versus nondiabetic NISCM , half ( n=20 ) subject enrol diabetic Subjects HF deem ischemic , congenital , valvular , infiltrative etiology , chemotherapy/toxininduced eligible enrollment . Other exclusion criterion include presence lifethreatening illness project survival ≤6 month ; recurrent ventricular arrhythmia ; endstage renal failure ; ongoing infection ; inability followup ; collagen vascular disease ( lupus , sarcoid ) ; enrollment another investigational study ; unstable symptomatic peripheral artery disease ; prior active Zn supplementation ; ongoing alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Cardiomyopathy</keyword>
	<keyword>Remodeling</keyword>
	<keyword>Antioxidant</keyword>
	<keyword>Zinc</keyword>
	<keyword>Copper</keyword>
</DOC>